Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant staphylococcus aureus infections in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 50-58

  Garzoni, C ^a,b   Vergidis, P ^c  

^a Clinica Luganese   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Antibiotic resistance; bacterial infection; multidrug resistance; posttransplant infection

Indexed keywords

CEFOXITIN; CEFTAROLINE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; METICILLIN; OXACILLIN; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BONE AND JOINT INFECTIONS; CREATININE CLEARANCE; DNA SEQUENCE; ENDOCARDITIS; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT RECIPIENT; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSTHETIC VALVE ENDOCARDITIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SKIN AND SOFT TISSUE INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; THROMBOCYTOPENIA; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;

HUMANS; METHICILLIN RESISTANCE; ORGAN TRANSPLANTATION; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 84874878077     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12098     Document Type: Article

References (90)

1. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK,. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301: 727-736.
2. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304: 641-648.
3. Kock R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus (MRSA): Burden of disease and control challenges in Europe. Euro Surveill 2010; 15: 19688.
4. European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2010. Stockholm: ECDC; 2010; Available from: http://ecdc.europa.eu/en/publications/Publications/1011- SUR-Annual-Epidemiological-Report-on-Communicable-Diseases-in-Europe.pdf
5. European Centre for Disease Prevention and Control. Annual Epidemiological Report on Communicable Diseases in Europe 2009. Stockholm: ECDC; 2009; Available from: www.ecdc.europa.eu/./0910-sur-annual-epidemiological- report-on-communicable-diseases-in-europe.pdf
6. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
7. Bert F, Larroque B, Paugam-Burtz C, et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes. Liver Transpl 2010; 16: 393-401.
8. Lee SO, Kang SH, Abdel-Massih RC, Brown RA, Razonable RR,. Spectrum of early-onset and late-onset bacteremias after liver transplantation: Implications for management. Liver Transpl 2011; 17: 733-741.
9. Malinis MF, Mawhorter SD, Jain A, Shrestha NK, Avery RK, van Duin D,. Staphylococcus aureus bacteremia in solid organ transplant recipients: Evidence for improved survival when compared with nontransplant patients. Transplantation 2012; 93: 1045-1050.
10. Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T,. Bacteremias in liver transplant recipients: Shift toward gram-negative bacteria as predominant pathogens. Liver Transpl 2004; 10: 844-849.
11. Bonatti H, Pruett TL, Brandacher G, et al. Pneumonia in solid organ recipients: Spectrum of pathogens in 217 episodes. Transplant Proc 2009; 41: 371-374.
12. Gupta MR, Valentine VG, Walker JE, et al. Clinical spectrum of gram-positive infections in lung transplantation. Transpl Infect Dis 2009; 11: 424-431.
13. Manuel O, Lien D, Weinkauf J, Humar A, Cobos I, Kumar D,. Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-year review of clinical and molecular epidemiology. J Heart Lung Transplant 2009; 28: 1231-1236.
14. Asensio A, Guerrero A, Quereda C, Lizan M, Martinez-Ferrer M,. Colonization and infection with methicillin-resistant Staphylococcus aureus: Associated factors and eradication. Infect Control Hosp Epidemiol 1996; 17: 20-28.
15. Singh N, Paterson DL, Chang FY, et al. Methicillin-resistant Staphylococcus aureus: The other emerging resistant Gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000; 30: 322-327.
16. Bert F, Bellier C, Lassel L, et al. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl 2005; 11: 1093-1099.
17. Florescu DF, McCartney AM, Qiu F, et al. Staphylococcus aureus infections after liver transplantation. Infection 2011.
18. Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz LD,. Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 2009; 30: 4-8.
19. Stone A, Quittell L, Zhou J, et al. Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts. Pediatr Infect Dis J 2009; 28: 895-899.
20. Santoro-Lopes G, de Gouvea EF, Monteiro RC, et al. Colonization with methicillin-resistant Staphylococcus aureus after liver transplantation. Liver Transpl 2005; 11: 203-209.
21. Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV,. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol 2006; 27: 122-126.
22. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005; 5: 751-762.
23. Bert F, Galdbart JO, Zarrouk V, et al. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis 2000; 31: 1295-1299.
24. Desai D, Desai N, Nightingale P, Elliott T, Neuberger J,. Carriage of methicillin-resistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl 2003; 9: 754-759.
25. Russell DL, Flood A, Zaroda TE, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant 2008; 8: 1737-1743.
26. Davis KA, Stewart JJ, Crouch HK, Florez CE, Hospenthal DR,. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004; 39: 776-782.
27. Obed A, Schnitzbauer AA, Bein T, Lehn N, Linde HJ, Schlitt HJ,. Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation 2006; 81: 121-124.
28. David MZ, Daum RS,. Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23: 616-687.
29. Deleo FR, Otto M, Kreiswirth BN, Chambers HF,. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375: 1557-1568.
30. Moroney SM, Heller LC, Arbuckle J, Talavera M, Widen RH,. Staphylococcal cassette chromosome mec and Panton-Valentine leukocidin characterization of methicillin-resistant Staphylococcus aureus clones. J Clin Microbiol 2007; 45: 1019-1021.
31. Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53: 144-149.
32. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-1771.
33. Tenover FC, Goering RV,. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother 2009; 64: 441-446.
34. Denis O, Deplano A, De Beenhouwer H, et al. Polyclonal emergence and importation of community-acquired methicillin-resistant Staphylococcus aureus strains harbouring Panton-Valentine leucocidin genes in Belgium. J Antimicrob Chemother 2005; 56: 1103-1106.
35. Larsen AR, Stegger M, Bocher S, Sorum M, Monnet DL, Skov RL,. Emergence and characterization of community-associated methicillin-resistant Staphyloccocus aureus infections in Denmark, 1999 to 2006. J Clin Microbiol 2009; 47: 73-78.
36. Johnson AP,. Methicillin-resistant Staphylococcus aureus: The European landscape. J Antimicrob Chemother 2011; 66 (Suppl 4): iv43-iv48.
37. Navarro MB, Huttner B, Harbarth S,. Methicillin-resistant Staphylococcus aureus control in the 21st century: Beyond the acute care hospital. Curr Opin Infect Dis 2008; 21: 372-379.
38. Boucher HW, Corey GR,. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 (Suppl 5): S344-349.
39. Adeyemi OA, Qi C, Zembower TR, et al. Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation. J Clin Microbiol 2008; 46: 2809-2813.
40. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML,. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
41. Richter SS, Satola SW, Crispell EK, et al. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J Clin Microbiol 2011; 49: 4203-4207.
42. Bert F, Clarissou J, Durand F, et al. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol 2003; 41: 5147-5152.
43. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC,. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46: 668-674.
44. Saha B, Singh AK, Ghosh A, Bal M,. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 2008; 57 (Pt 1): 72-79.
45. Aligholi M, Emaneini M, Jabalameli F, Shahsavan S, Dabiri H, Sedaght H,. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 2008; 17: 432-434.
46. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
47. Wellinghausen N, Siegel D, Gebert S, Winter J,. Rapid detection of Staphylococcus aureus bacteremia and methicillin resistance by real-time PCR in whole blood samples. Eur J Clin Microbiol Infect Dis 2009; 28: 1001-1005.
48. Gonzalez V, Padilla E, Gimenez M, et al. Rapid diagnosis of Staphylococcus aureus bacteremia using S. aureus PNA FISH. Eur J Clin Microbiol Infect Dis 2004; 23: 396-398.
49. Lagace-Wiens PR, Adam HJ, Karlowsky JA, et al. Identification of blood culture isolates directly from positive blood cultures using MALDI-TOF mass spectrometry and a commercial extraction system-analysis of performance, cost and turnaround time. J Clin Microbiol 2012; 50: 3324-3328.
50. Carson J, Lui B, Rosmus L, Rennick H, Fuller J,. Interpretation of MRSASelect screening agar at 24 hours of incubation. J Clin Microbiol 2009; 47: 566-568.
51. Warren DK, Liao RS, Merz LR, Eveland M, Dunne WM, Jr,. Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay. J Clin Microbiol 2004; 42: 5578-5581.
52. Broekema NM, Van TT, Monson TA, Marshall SA, Warshauer DM,. Comparison of cefoxitin and oxacillin disk diffusion methods for detection of mecA-mediated resistance in Staphylococcus aureus in a large-scale study. J Clin Microbiol 2009; 47: 217-219.
53. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-8th Ed. CLSI document M07-A8, Vol. 29 No 2. Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
54. Holmes NE, Johnson PD, Howden BP,. The relationship between hVISA, VISA, high vancomycin MIC and outcome in serious Staphylococcus aureus infection. J Clin Microbiol 2012; 50: 2548-2552.
55. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011; 52: 285-292.
56. Hageman JC, Patel JB, Carey RC, Tenover FC, Mcdonald LC,. Investigation and Control of Vancomycin-Intermediate and -Resistant Staphylococcus Aureus: A Guide for Health Departments and Infection Control Personnel. Atlanta, GA, 2006; Available from: http://www.cdc.gov/hai/pdfs/visa-vrsa/visa-vrsa-guide.pdf
57. Appelbaum PC,. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007; 30: 398-408.
58. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-327.
59. van Hal SJ, Lodise TP, Paterson DL,. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-771.
60. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521-528.
61. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: A large, multicenter, retrospective study. Pharmacotherapy 2011; 31: 527-536.
62. Falagas ME, Manta KG, Ntziora F, Vardakas KZ,. Linezolid for the treatment of patients with endocarditis: A systematic review of the published evidence. J Antimicrob Chemother 2006; 58: 273-280.
63. Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: Efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49: 395-401.
64. Sander A, Beiderlinden M, Schmid EN, Peters J,. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med 2002; 28: 1157-1160.
65. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS, 2nd,. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012; 67: 1267-1270.
66. Nace H, Lorber B,. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010; 65: 1315-1316.
67. Fowler VG, Jr., Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665.
68. Levine DP, Lamp KC,. Daptomycin in the treatment of patients with infective endocarditis: Experience from a registry. Am J Med 2007; 120 (10 Suppl 1): S28-S33.
69. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Jr., Eliopoulos GM,. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50: 1581-1585.
70. Radunz S, Juntermanns B, Kaiser GM, et al. Efficacy and safety of linezolid in liver transplant patients. Transpl Infect Dis 2011; 13: 353-358.
71. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study. Clin Infect Dis 2012; 54: 621-629.
72. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E,. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 (Suppl 5): S341-S353.
73. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ,. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-1229.
74. Yahav D, Lador A, Paul M, Leibovici L,. Efficacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1963-1971.
75. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-650.
76. File TM, Jr., Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: Randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-1405.
77. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-1693.
78. Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE,. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: A randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279: 1537-1541.
79. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE,. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202-211.
80. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications. Circulation 2005; 111: e394-e434.
81. Calfee DP, Salgado CD, Classen D, et al. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 (Suppl 1): S62-S80.
82. Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006; 63 (Suppl 1): S1-S44.
83. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-386.
84. Siegel JD, Rhinehart E, Jackson M, Chiarello L,. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007; 35 (10 Suppl 2): S165-S193.
85. Pittet D, Hugonnet S, Harbarth S, et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000; 356: 1307-1312.
86. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362: 9-17.
87. van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA,. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: A systematic review. J Antimicrob Chemother 2008; 61: 254-261.
88. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D,. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1412-1416.
89. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE,. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.
90. Paterson DL, Rihs JD, Squier C, Gayowski T, Sagnimeni A, Singh N,. Lack of efficacy of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplant recipients and candidates. Transplantation 2003; 75: 194-198.